Commentary on the Royalty Pharma Ruling of the CJEU of 30 April 2020. Full text: Comunicaciones ENG oct 2020 pag
Home » The two-part test for grant of supplementary protection certificates is here to stay, but at what price?
Commentary on the Royalty Pharma Ruling of the CJEU of 30 April 2020. Full text: Comunicaciones ENG oct 2020 pag
This paper analyses the promotion of medicines for human use that have already received marketing authorization, when the advertising is made before the resolution on pricing and inclusion in the Spanish National Health Service. This is an issue addressed by
Three of the most recognized experts on IP farma in Spain Ángel García Vidal, profesor de Derecho Mercantil de la Universidad de Santiago de Compostela y Consejero Académico de Gómez Acebo y Pombo, Kiko Carrión García de Parada, Abogado socio
Jorge Muñoz, Member of CEFI Board lead the debate on advanced therapies an biological medicinal products. Sol Ruíz, Jefe de División de Productos Biológicos, Terapias Avanzadas y Biotecnología de la Agencia Española de Medicamentos y Productos Sanitarios and Jordi Faus,
Interesting debate with Jesús Rubí, Adjunto a la Dirección de la Agencia Española de Protección de Datos, Amelia Martín Uranga, Responsable de la Plataforma de Medicamentos Innovadores de Farmaindustria and Lluis Alcover, Abogado de Faus y Moliner. Interestingf debate about main
On 15 October we had an interesting discussion on Observational Studies on Medications and patient support programmes in the new regulations that aroused a lot of interest. More than 90 people participated in the session with strong participation in questions
Superior Court of Justice of the Basque Country, Judicial Review Chamber, Judgment 246/2021 of 30 June resolved positively on a question widely debated in the sector: the possibility of advertising medicinal products that have been approved for sale but have
A foundation for promoting and supporting research and technological development, especially regarding the pharmaceutical industry